A Phase 1, First-in-human Study of VX-668

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.

Phase 1

Vertex Pharmaceuticals Incorporated